Skip Nav Destination
OnlineFirst
Research Article December 6 2023
TAS0313 Plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor-Naïve Locally Advanced or Metastatic Urothelial Carcinoma
Hiroyuki Nishiyama; Junji Yonese; Takashi Kawahara; Ryuji Matsumoto; Hideaki Miyake; Nobuaki Matsubara; Hiroji Uemura; Masatoshi Eto; Haruhito Azuma; Wataru Obara; Akito Terai; Satoshi Fukasawa; Shigetaka Suekane
Mol Cancer Ther (2023)
Models and Technologies December 6 2023
SKP2 Knockout in Rb1/p53–Deficient Mouse Models of Osteosarcoma Induces Immune Infiltration and Drives a Transcriptional Program with a Favorable Prognosis
Alexander Ferrena; Jichuan Wang; Ranxin Zhang; Burcu Karadal-Ferrena; Waleed Al-Hardan; Swapnil Singh; Hasibagan Borjihan; Edward L. Schwartz; Hongling Zhao; Maja H. Oktay; Rui Yang; David S. Geller; Bang H. Hoang; Deyou Zheng
Mol Cancer Ther (2023)
Research Article December 6 2023
Combination therapy with EGFR tyrosine kinase inhibitors and TEAD inhibitor increases tumor suppression effects in EGFR mutation-positive lung cancer
Tatsuya Ogimoto; Hiroaki Ozasa; Takahiro Tsuji; Tomoko Funazo; Masatoshi Yamazoe; Kentaro Hashimoto; Hiroshi Yoshida; Kazutaka Hosoya; Hitomi Ajimizu; Takashi Nomizo; Hironori Yoshida; Masatsugu Hamaji; Toshi Menju; Akihiko Yoshizawa; Hiroshi Date; Toyohiro Hirai
Mol Cancer Ther (2023)
Targeting Drug Resistance December 5 2023
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms
Alberto J. Arribas; Sara Napoli; Luciano Cascione; Laura Barnabei; Giulio Sartori; Eleonora Cannas; Eugenio Gaudio; Chiara Tarantelli; Afua A. Mensah; Filippo Spriano; Antonella Zucchetto; Francesca M. Rossi; Andrea Rinaldi; Manuel Castro de Moura; Sandra Jovic; Roberta Bordone Pittau; Anastasios Stathis; Georg Stussi; Valter Gattei; Jennifer R. Brown; Manel Esteller; Emanuele Zucca; Davide Rossi; Francesco Bertoni
Mol Cancer Ther (2023)
Small Molecule Therapeutics December 5 2023
Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung Metastasis
Amriti R. Lulla; Said Akli; Cansu Karakas; Joseph A. Caruso; Lucas D. Warma; Natalie W. Fowlkes; Xiayu Rao; Jing Wang; Kelly K. Hunt; Stephanie S. Watowich; Khandan Keyomarsi
Mol Cancer Ther (2023)
Large Molecule Therapeutics December 5 2023
Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody–Drug Conjugates
Saskia Schmitt; Paul Machui; Isabelle Mai; Sarah Herterich; Swetlana Wunder; Philipp Cyprys; Marcus Gerlach; Philipp Ochtrop; Christian P.R. Hackenberger; Dominik Schumacher; Jonas Helma; Annette M. Vogl; Marc-André Kasper
Mol Cancer Ther (2023)
Review December 5 2023
Structural Insight into Geranylgeranyl Diphosphate Synthase (GGDPS) for Cancer Therapy
Mol Cancer Ther (2023)
Models and Technologies December 5 2023
Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models
Kanae Imai; Yuki Takeuchi; Seitaro Terakura; Shingo Okuno; Yoshitaka Adachi; Masahide Osaki; Koji Umemura; Ryo Hanajiri; Kazuyuki Shimada; Makoto Murata; Hitoshi Kiyoi
Mol Cancer Ther (2023)
Subject Review December 5 2023
Roles of cGAS-STING pathway in radiotherapy combined with immunotherapy for hepatocellular carcinoma
Mol Cancer Ther (2023)
Research Article November 30 2023
Darolutamide added to docetaxel augments antitumor effect in models of prostate cancer through cell cycle arrest at the G1-S transition
Stefan A.J. Buck; Annelies Van Hemelryk; Corrina de Ridder; Debra Stuurman; Sigrun Erkens-Schulze; Sem Van 't Geloof; Wilma J. Teubel; Stijn L.W. Koolen; Elena S. Martens-Uzunova; Martin E. van Royen; Ronald de Wit; Ron H. J. Mathijssen; Wytske M. van Weerden
Mol Cancer Ther (2023)
First Disclosure November 30 2023
XTX301, a tumor-activated Interleukin-12 has the potential to widen the therapeutic index of IL-12 treatment for solid tumors as evidenced by pre-clinical studies
Ekta Patel; Natalia V. Malkova; David Crowe; Magali Pederzoli-Ribeil; Damiano Fantini; Manoussa Fanny; Hanumantha Rao Madala; Kurt A. Jenkins; Oleg Yerov; Justin Greene; Wilson Guzman; Caitlin O'Toole; Jacob Taylor; Rebekah K. O’Donnell; Parker Johnson; Bernard B. Lanter; Brian Ames; Jia Chen; Sallyann Vu; Hsin-Jung Wu; Susan Cantin; Megan McLaughlin; Yu-Shan S. Hsiao; Dheeraj S. Tomar; Raphael Rozenfeld; Lakshmanan Thiruneelakantapillai; Ronan C. O’Hagan; Benjamin Nicholson; Jennifer O’Neil; Carl Uli Bialucha
Mol Cancer Ther (2023)
Research Article November 30 2023
Glucocorticoid receptor (GR) activation is associated with increased cAMP/PKA signaling in castrate-resistant prostate cancer
Lynda Bennett; Praveen Kumar. Jaiswal; Ryan V. Harkless; Tiha M. Long; Ning Gao; Brianna Vandenburg; Phillip Selman; Ishrat Durdana; Ricardo R. Lastra; Donald Vander Griend; Remi Adelaiye-Ogala; Russell Z. Szmulewitz; Suzanne D. Conzen
Mol Cancer Ther (2023)
Research Article November 28 2023
Circulating oncometabolite 2-hydroxyglutarate (2HG) as a potential biomarker for isocitrate dehydrogenase (IDH1/2) mutant cholangiocarcinoma
Cha Len Lee; Grainne M. O'Kane; Warren P. Mason; Wen-Jiang Zhang; Pavlina Spiliopoulou; Aaron R. Hansen; Robert C. Grant; Jennifer J. Knox; Tracy L. Stockley; Gelareh Zadeh; Eric X. Chen
Mol Cancer Ther (2023)
Subject Review November 28 2023
Targeting Dysregulated Ion Channels in Liver Tumors with Venom Peptides
Mol Cancer Ther (2023)
Research Article November 23 2023
PUMA/RIP3 mediates chemotherapy response via necroptosis and local immune activation in colorectal cancer
Dongshi Chen; Kaylee Ermine; Yi-Jun Wang; Xiaojun Chen; Xinyan Lu; Peng Wang; Donna Beer-Stolz; Jian Yu; Lin Zhang
Mol Cancer Ther (2023)
Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers November 22 2023
Amelioration of Tumor-promoting Microenvironment via Vascular Remodeling and CAF Suppression Using E7130: Biomarker Analysis by Multimodal Imaging Modalities
Ken Ito; Masayuki Yamaguchi; Taro Semba; Kimiyo Tabata; Moe Tamura; Muneo Aoyama; Takanori Abe; Osamu Asano; Yasuhiko Terada; Yasuhiro Funahashi; Hirofumi Fujii
Mol Cancer Ther (2023)
Large Molecule Therapeutics November 22 2023
An Antibody–Drug Conjugate Directed to Tissue Factor Shows Preclinical Antitumor Activity in Head and Neck Cancer as a Single Agent and in Combination with Chemoradiotherapy
Jantine E. Bakema; Marijke Stigter-van Walsum; Jeffrey R. Harris; Sonja H. Ganzevles; Anantharaman Muthuswamy; Mischa Houtkamp; Theo S. Plantinga; Elisabeth Bloemena; Ruud H. Brakenhoff; Esther C.W. Breij; Rieneke van de Ven
Mol Cancer Ther (2023)
Targeting Drug Resistance November 22 2023
Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells
Soichi Hirai; Tadaaki Yamada; Yuki Katayama; Masaki Ishida; Hayato Kawachi; Yohei Matsui; Ryota Nakamura; Kenji Morimoto; Mano Horinaka; Toshiyuki Sakai; Yoshitaka Sekido; Shinsaku Tokuda; Koichi Takayama
Mol Cancer Ther (2023)
Research Article November 18 2023
Oncogenic cells of renal embryonic lineage sensitive to the small molecule inhibitor QC6352 display depletion of KDM4 levels and disruption of ribosome biogenesis
Prahalathan Pichavaram; Carolyn M. Jablonowski; Jie Fang; Andrew M. Fleming; Hyea Jin Gil; Andrew S. Boghossian; Matthew G. Rees; Melissa M. Ronan; Jennifer A. Roth; Christopher L. Morton; Gerard P. Zambetti; Andrew M. Davidoff; Jun Yang; Andrew J. Murphy
Mol Cancer Ther (2023)
Subject Review November 18 2023
Interleukin 35: New Target for Immunotherapy Targeting the Tumor Microenvironment
Mol Cancer Ther (2023)
Small Molecule Therapeutics November 17 2023
Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant In Vivo Efficacy in Glioblastoma
Wenjuan Zhang; Rachael A. Vaubel; Ju-Hee Oh; Ann C. Mladek; Surabhi Talele; Wenqiu Zhang; Katie L. Waller; Danielle M. Burgenske; Jann N. Sarkaria; William F. Elmquist
Mol Cancer Ther (2023)
First Disclosure November 16 2023
CD38 x ICAM-1 Bispecific Antibody Is a Novel Approach for Treating Multiple Myeloma and Lymphoma
Mol Cancer Ther (2023)
Large Molecule Therapeutics November 16 2023
Brentuximab Vedotin–Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity
Ryan A. Heiser; Anthony T. Cao; Weiping Zeng; Michelle Ulrich; Patrick Younan; Martha E. Anderson; Esther S. Trueblood; Mechthild Jonas; Robert Thurman; Che-Leung Law; Shyra J. Gardai
Mol Cancer Ther (2023)
First Disclosure November 15 2023
A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models
Hanne Hillen; Aurélie Candi; Bart Vanderhoydonck; Weronika Kowalczyk; Leticia Sansores-Garcia; Elena C. Kesikiadou; Leen Van Huffel; Lore Spiessens; Marnik Nijs; Erik Soons; Wanda Haeck; Hugo Klaassen; Wim Smets; Stéphane A. Spieser; Arnaud Marchand; Patrick Chaltin; Fabrice Ciesielski; Francois Debaene; Lei Chen; Adeela Kamal; Stephen L. Gwaltney; Matthias Versele; Georg A. Halder
Mol Cancer Ther (2023)
Research Article November 15 2023
The antipsychotic drug penfluridol inhibits N-linked glycoprotein processing and enhances T-cell-mediated tumor immunity
Wenlong Xu; Yuqi Wang; Na Zhang; Xiaofeng Lin; Di Zhu; Cheng Shen; Xiaobo Wang; Haiyang Li; Jinjiang Xue; Qian Yu; Xinyi Lu; Lu Zhou; Qingli He; Zhijun Tang; Shaodan He; Jianjun Fan; Jianbo Pan; Jiangjiang Tang; Wei Jiang; Mingliang Ye; Fanghui Lu; Zengxia Li; Yongjun Dang
Mol Cancer Ther (2023)
Research Article November 11 2023
Radiation Synergizes with IL-2/IL-15 Stimulation to Enhance Innate Immune Activation and Antitumor Immunity
Xuefeng Li; Kristin Huntoon; Yifan Wang; DaeYong Lee; Shiyan Dong; Abin Antony; Carl Walkey; Betty Y.S. Kim; Wen Jiang
Mol Cancer Ther (2023)
Large Molecule Therapeutics November 9 2023
Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Susan M. Clardy; Alex Uttard; Bingfan Du; Kalli C. Catcott; Kelly L. Lancaster; Elizabeth Ditty; Jack Sadowsky; Jeffrey Zurita; Naniye Malli; LiuLiang Qin; Stephen P. Bradley; Kenneth Avocetien; Tyler Carter; Dokyong Kim; Mark Nazzaro; Ling Xu; Thomas H. Pillow; Neelie T. Zacharias; Gail D. Lewis; Rebecca K. Rowntree; Radha Iyengar; David H. Lee; Marc Damelin; Dorin Toader; Timothy B. Lowinger
Mol Cancer Ther (2023)
Small Molecule Therapeutics November 9 2023
Bruton's Tyrosine Kinase Inhibitors with Distinct Binding Modes Reveal Differential Functional Impact on B-Cell Receptor Signaling
Wei Li; Renata Sano; Mutiah Apatira; Felix DeAnda; Tarikere Gururaja; Muhua Yang; Greta Lundgaard; Chin Pan; Jing Liu; Yongjiao Zhai; Woo Hyun Yoon; Longcheng Wang; Chris Tse; Andrew J. Souers; Chih-Hung Lee
Mol Cancer Ther (2023)
Large Molecule Therapeutics November 9 2023
Targeting NANOG and FAK via Cx26-derived Cell-penetrating Peptides in Triple-negative Breast Cancer
Erin E. Mulkearns-Hubert; Emily Esakov Rhoades; Salma Ben-Salem; Rashmi Bharti; Nicole Hajdari; Sadie Johnson; Alex Myers; Iris Nira Smith; Smarajit Bandyopadhyay; Charis Eng; Erinn Downs; Justin D. Lathia; Ofer Reizes
Mol Cancer Ther (2023)
Research Article November 8 2023
Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models
Manja Friese-Hamim; Maria J. Ortiz-Ruiz; Olga Bogatyrova; Marina Keil; Felix Rohdich; Beatrix Blume; Birgitta Leuthner; Frank Czauderna; Diane Hahn; Julia Jabs; Frank Jaehrling; Timo Heinrich; Roland Kellner; Katherine Chan; Amy H. Y. Tong; Dirk Wienke; Jason Moffat; Andree Blaukat; Frank T. Zenke
Mol Cancer Ther (2023)
Research Article November 3 2023
Genetic silencing of AKT induces melanoma cell death via mTOR suppression
Gennie L. Parkman; Tursun Turapov; David A. Kircher; William J. Burnett; Christopher M. Stehn; Kayla O'Toole; Katie M. Culver; Ashley T. Chadwick; Riley C. Elmer; Ryan Flaherty; Karly A. Stanley; Mona Foth; David H. Lum; Robert L. Judson-Torres; John E. Friend; Matthew W. VanBrocklin; Martin McMahon; Sheri L. Holmen
Mol Cancer Ther (2023)
Research Article November 1 2023
Improving Intracellular Delivery of an Antibody-Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo
Ian Nessler; Baron Rubahamya; Anna Kopp; Scott Hofsess; Thomas M. Cardillo; Nalini Sathyanarayan; Jennifer Donnell; Serengulam V. Govindan; Greg M. Thurber
Mol Cancer Ther (2023)
Targeting Drug Resistance November 1 2023
MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling
Nan Chen; Logan C. Tyler; Anh T. Le; Eric A. Welsh; Bin Fang; Andrew Elliott; Kurtis D. Davies; Thomas Danhorn; Gregory J. Riely; Marc Ladanyi; Eric B. Haura; Robert C. Doebele
Mol Cancer Ther (2023)
Small Molecule Therapeutics November 1 2023
Targeting DNA Repair and Survival Signaling in Diffuse Intrinsic Pontine Gliomas to Prevent Tumor Recurrence
Monika Sharma; Ivana Barravecchia; Robert Teis; Jeanette Cruz; Rachel Mumby; Elizabeth K. Ziemke; Carlos E. Espinoza; Varunkumar Krishnamoorthy; Brian Magnuson; Mats Ljungman; Carl Koschmann; Joya Chandra; Christopher E. Whitehead; Judith S. Sebolt-Leopold; Stefanie Galban
Mol Cancer Ther (2023)
Research Article October 31 2023
TAS0612, a novel RSK, AKT, and S6K inhibitor, exhibits antitumor effects in preclinical tumor models
Koji Ichikawa; Satoshi Ito; Emi Kato; Naomi Abe; Takumitsu Machida; Junya Iwasaki; Gotaro Tanaka; Hikari Araki; Kentaro Wakayama; Hideki Jona; Tetsuya Sugimoto; Kazutaka Miyadera; Shuichi Ohkubo
Mol Cancer Ther (2023)
Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers October 31 2023
SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma
Hidehiko Akashi; Nozomi Yachida; Haruka Ueda; Manako Yamaguchi; Kaoru Yamawaki; Ryo Tamura; Kazuaki Suda; Tatsuya Ishiguro; Sosuke Adachi; Yoshikazu Nagase; Yutaka Ueda; Masashi Ueda; Kaoru Abiko; Masahiro Kagabu; Tsukasa Baba; Hirofumi Nakaoka; Takayuki Enomoto; Junko Murai; Kosuke Yoshihara
Mol Cancer Ther (2023)
Subject Review October 30 2023
Adoptive T cells therapy in solid tumors: state-of-the art, current challenges, and upcoming improvements
Mol Cancer Ther (2023)
Research Article October 11 2023
Bifunctional inhibitor reveals NEK2 as a therapeutic target and regulator of oncogenic pathways in lymphoma
Mason McCrury; Kennith Swafford; Sydnye L. Shuttleworth; Syed Hassan. Mehdi; Baku Acharya; Debasmita Saha; Kevin Naceanceno; Stephanie D. Byrum; Aaron J. Storey; Ying-Zhi Xu; Claire Doshier; Vijay Patel; Ginell R. Post; Annick De Loose; Analiz Rodriguez; Leonard D. Shultz; Fenghuang Zhan; Donghoon Yoon; Brendan Frett; Samantha Kendrick
Mol Cancer Ther (2023)
Advertisement
